COLCORONA trial in patients with COVID-19 passes futility test in interim analysisHome > Press room > COLCORONA trial in patients with COVID-19 passes futility test in interim analysis
June 26, 2020
Colchicine, a common drug to treat gout, is being evaluated as a potential treatment in the fight against coronavirus
Montreal Heart Institute today announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee (DMC), following a futility analysis.
“We are pleased to have achieved this important milestone and now await the final results of COLCORONA, to determine the effect of colchicine in preventing complications in non-hospitalized patients with COVID-19,” said Dr. Jean-Claude Tardif, Director of the Research Center at MHI, Professor of Medicine at the University of Montreal, and COLCORONA primary investigator. “We are committed to including large number of patients worldwide in this robust study to determine the effect of colchicine on the serious inflammatory storm seen with COVID-19, potentially keeping patients out of the hospital and ultimately saving lives”.find out more by visiting the Institute’s website